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a b s t r a c t
Drug-eluting stents have revolutionised the treatment of coronary artery disease. These small medical
devices have attracted much interest over the past decade from biologists, clinicians, engineers and
mathematicians alike. This article provides a comprehensive review of the modelling of drug release from
arterial stents and the subsequent drug transport through arterial tissue, and acts as a useful reference
equally for those who are already involved in drug-eluting stents research and for those who are starting
out in the field. Assembled in this review are the main models of drug release and arterial drug transport
that have been published in the literature to date. Many of the models presented in this paper have
evolved from drug transport models in other applications. Furthermore, the ideas presented in this
review may also be extended to other drug-delivery applications, such as drug coated balloons, transder-
mal patches and therapeutic contact lenses.
 2014 The Author. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/3.0/).
1. Introduction and Background
Arterial stents have revolutionised the treatment of coronary
heart disease (CHD). Acting as a supporting scaffold, these small
mesh devices are now routinely inserted into arteries where the
blood flow has become dangerously restricted (see Fig. 1). There
are many benefits to the patient over more traditional treatment
strategies such as open-heart surgery, including a lower incidence
of major complications and an expedited recovery time. Further-
more, most patients do not require general anesthesia. Over the
past decade, arterial stents have evolved from mere bare metal
scaffolds to polymer coated drug-delivery vehicles and, more
recently, sophisticated fully biodegradable drug delivery configu-
rations. The driver behind these continuing advances is the desire
to improve clinical outcomes. The original bare metal stents, while
revolutionary at the time, were soon rendered unsatisfactory due
to the relatively quick occurrence of restenosis, the re-narrowing
of the lumen. The next wave of arterial stents included a drug
designed to prevent the occurrence of restenosis: these are the
so-called drug-eluting stents (DESs). The development of these
stents threw up all sorts of questions such as: What type of drug
should be used? How much drug should be coated on the stent?
How will the drug release be controlled? Effective DES design
became the priority for many of the top medical device companies,
with considerable budgets spent on developing these products. In
2002 the first-generation DESs, Cypher (sirolimus-eluting stent;
Cordis Corporation) and Taxus (paclitaxel-eluting stent; Boston
Scientific Corporation) arrived. They comprised a stainless steel
platform with a drug containing polymer coating attached to the
stent struts [1,2]. The philosophy behind this design was to allow
the drug to be released gradually so as to avoid toxic levels of drug
initially, but also to permit sustained delivery over many weeks.
The Cypher stent actually consists of multiple polymer layers
designed to enhance the controlled nature of the release. The drugs
used (sirolimus and paclitaxel) are both lipophilic and are able to
inhibit smooth muscle cell (SMC) proliferation and migration.
The second-generation DESs Endeavor (zotarolimus-eluting;
Medtronic), Promus (everolimus-eluting; Boston Scientific
Corporation) and Xience V (everolimus eluting; Abbott Laborato-
ries) attempted to improve the biocompatibility and reduce the
incidence of thrombosis which was associated with first-genera-
tion DES [3,4]. These stents were generally designed with thinner
struts and utilised cobalt-chromium and platinum chromium plat-
forms. A variety of multi-layer polymer combinations were used on
these stents to attempt to control the release. Generally these
stents have been shown to exhibit lower thrombosis rates com-
pared with first generation DES [5]. Since the polymer coating in
the earlier DES has been associated with a local vascular inflamma-
tory reaction and potentially inducing late stent thrombosis, newer
generation stents have focussed on biodegradable polymers (BioM-
atrix, Biosensors Inc, Nobori, Terumo, and Synergy, Boston Scien-
tific Corporation), where the polymer carries and controls the
drug release and then erodes or vanishes, and also coatings which
do not contain any polymer at all (Yukon, Translumina and
BioFreedom, Biosensors Inc), with the drug being contained on a
modified surface of the stent. Perhaps the most sophisticated
to date is the completely bioresorbable stent Absorb (Abbott
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Laboratories). This stent elutes everolimus in a similar way to
Xience V and then resorbs naturally into the body leaving no
permanent scaffold.
A significant amount of research has gone into the development
of arterial stents. Countless experiments have been performed
(many of which involving animals), not to mention the need for
clinical trials before accreditation is finally granted. The long
treacherous and costly road from a good stent design idea to regu-
latory approval has led many to question whether modelling could
be better used to try to make this path an easier one. Indeed, only
those stents which show promising results in laboratory and clin-
ical trials are retained and those that do not are discarded – often
after considerable investment. Mathematicians and engineers,
realising that this complex problem is amenable to modelling, have
become increasingly interested over the years. In the early years
the drug release mechanism was very poorly understood, but
through mathematical modelling approaches, combined with
experiments, researchers have helped identify the dominant
mechanisms of release in a number of stents. While release exper-
iments alone can give information regarding the release profile and
the duration of release, the data generated is for one particular set
of parameters (e.g. coating thickness, drug type and concentration)
and the experiment needs to be repeated for each new parameter
considered. Once verified, mathematical models have the advan-
tage of allowing several parameters to be varied and the release
profiles compared without the need to repeat the experiments.
The ability of a mathematical model to help identify the important
parameters that govern the drug release is invaluable. Modelling
can also play an important role when an understanding of the drug
distribution within arterial tissue is required. Cardiologists will
often stress that uniform drug concentrations across the wall are
desired, and that these concentrations should be maintained
within some minimum therapeutic and toxic levels. Obtaining this
kind of information from experiments is extremely challenging, yet
free and bound drug concentration profiles can readily be output
from a mathematical model. But experiments and modelling must
go hand in hand: the accuracy of the model results can only ever be
as good as the quality of the inputs, especially when the model is
sensitive to changes in one or more of the parameters. Indeed,
the accurate determination of system parameters remains one of
the biggest challenges in the field due to the natural variation
between species and the complexity involved in making the
required measurements, especially in the in vivo situation.
However, some recent progress has been made by combining
in vitro/ex vivo experiments with simple mathematical models,
and this approachmay continue to yield useful results in the future.
Aswe shall see, the conclusionswhich can be drawn frommodelling
have provided useful insights, some of which are counter-intuitive.
Among the many other benefits of adopting a modelling approach
include the potential to indicate at an early stage the designs that
are doomed to failure, to design stents that are optimised and to
result in a reduction in the number of experiments required.
In this paper we provide a comprehensive review of the model-
ling of drug-release from arterial stents and the subsequent arterial
drug redistribution. We firstly present the models which have been
developed to describe drug release from DESs. Then, we consider
how drug uptake into arterial tissue has been modelled. Thirdly,
models which treat the stent and the arterial wall as a coupled
system are reported. The benefits and drawbacks of each model
are discussed. We have attempted to unite the various different
notations in the literature. With this in mind, the models presented
here may differ in notation from the original work.
2. Modelling the release of drug from arterial stents
An important aspect in the performance of any DES is the drug
release profile. If too much drug is delivered then toxicity can arise,
whereas if too little drug is delivered then it may have no effect at
all. Of course, this ‘‘therapeutic window’’ varies between drugs and
between patients and most probably with time after implantation
too. Stent manufacturers routinely test the release of drug from
their stents in an in vitro environment to gain an understanding
of the shape of the release profile and to compare the release pro-
file of different devices. This allows the manufacturers to ascertain
the repeatability of the release profile. Whilst the in vitro release is
Fig. 1. Illustration of a stent being inserted at the site of a blocked artery. Source: National Heart, Lung and Blood Institute; National Institute of Health; U.S. Department of
Health and Human Services.
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unlikely to replicate the in vivo situation, it is nonetheless an
important step in the development process. From the modelling
perspective it makes sense to start with simple models, and in
particular, it seems sensible to firstly consider modelling release
in a controlled in vitro environment before embarking on the
highly complex in vivo situation.
A number of authors have focussed specifically on modelling
the release of drug from DESs, electing to put to one side the range
of complexities that are observed in the in vivo situation (including
flowing blood, pulsatility, wound healing, proliferation, migration
of cells and complex uptake/binding). This approach has proven
to be useful in helping to address the question of what mecha-
nism(s) are behind the release of drug from a number of stent
systems and also in allowing estimates of parameter values
(e.g. diffusion coefficients) to be made. Of course, modelling drug
release is not an area of research exclusive to DESs. In fact,
scientists have been devising models which describe the release
of drug from tablet formulations and drug delivery devices for dec-
ades. It is therefore not a surprise that the early models of drug
release from DESs incorporated well-established ideas from other
applications.
2.1. Drug release from non-erodible polymer coated stents
Drug release from DESs comprising non-erodible polymers has
been modelled as a diffusion dominated process (see for example
[6–8]), with the drug concentration in the polymer Cp satisfying
a diffusion equation with drug diffusion coefficient Dp. The geom-
etry can be assumed to be that of a thin film of thickness Lp with no
edge effects so that the modelling may be simplified to one
dimension:
@Cp
@t
ðx; tÞ ¼ Dp @
2Cp
@x2
ðx; tÞ; x 2 ð0; LpÞ; t > 0: ð1Þ
In this one-dimensional setting, a zero-flux condition is normally
imposed since the stent is impermeable and the initial drug concen-
tration is taken to be uniform. McGinty et al. [9] impose perfect sink
conditions (Cp ¼ 0) where the drug meets the release medium
(these are conditions which can be controlled in the in vitro exper-
iment). Zhao et al. [10] presented a similar model, albeit in a cylin-
drical geometry, when describing the experimental drug release of
everolimus from a Dynalink-E polymer coated stent:
@Cp
@t
ðr; tÞ ¼ Dp @
2Cp
@r2
ðr; tÞ þ 1
r
@Cp
@r
ðr; tÞ
 !
; r 2 ða; bÞ; t > 0; ð2Þ
where, here, a is the inner radius (the boundary with the metal
stent), b is the outer radius (the boundary with the release medium)
and the same initial and boundary conditions as in the McGinty
et al. model are supposed. Each of these models admits an analytical
solution and has shown favourable results when compared with
in vitro experimental data. McGinty et al. and Zhao et al. provide
the respective solutions for the cumulative fraction of drug released
(Mfrac):
MfracðtÞ ¼ 1 8p2
X1
n¼1
1
2n 1ð Þ2
exp
 2n 1ð Þ2p2Dpt
4L2p
( )
; ð3Þ
MfracðtÞ ¼ 1 4
2aþ Lp
 
Lp
X1
n¼1
exp Dpa2nt
 
1 J20ðbanÞ=J21ðaanÞ
; ð4Þ
where an is the nth positive root of J1ðaanÞY0ðbanÞ
Y1ðaanÞJ0ðanÞ ¼ 0 with J0ðxÞ and J1ðxÞ Bessel functions of the first
kind of orders 0 and 1, and Y0ðxÞ and Y1ðxÞ are Bessel functions of
the second kind of orders 0 and 1, respectively. In each model the
diffusion coefficient is assumed to be constant. McGinty et al.
demonstrated that in vitro sirolimus release from the Cypher stent
was well described by (3) indicating that diffusion was the
dominant release mechanism. They estimated the diffusion coeffi-
cient to be of Oð1017Þm2 s1 via a best fitting process. Zhao et al.
also confirmed diffusion dominated release from the Dynalink stent
and they found that their model solution could be fitted to both
in vitro and in vivo release data simply by varying the coating
diffusion coefficient. But it is not clear why the coating diffusion
coefficient should be different in the two cases. They found that
for the in vivo release a diffusion coefficient approximately ten
times smaller than the in vitro release was required (Oð1017Þ and
Oð1016Þm2 s1, respectively).
Hossainy and Prabhu [11], in an attempt to predict the release
of everolimus from a biodurable fluoropolymer-based DES coating,
also adopted a diffusion based approach, but they assumed a bimo-
dal lumped-parameter model. Differently from the models of
McGinty et al. and Zhao et al. the assumption is made that the dis-
persed drug phase contributes to two discrete modes of drug trans-
port through the coating. The first mode is the fast one in which
drug is released from a highly percolated structure and the second
mode is the slow one where drug is released from a non-percolated
polymer encapsulated phase. Although Robin-type boundary
conditions are proposed, the parameter values chosen by the
authors are such that sink conditions are supposed. The result is
Eq. (1) for each mode of transport, with the same zero flux and infi-
nite sink boundary conditions. The difference between the two
modes is captured by a different diffusion coefficient. A further
parameter, a, which defines the ratio of drug in the first mode to
the total drug, is defined. The authors numerically obtain estimates
of the diffusion coefficients and a by way of a numerical error min-
imisation process. They utilise in vivo experimental data from a
porcine animal study. Good agreement between the model and
experiments is observed with the mode 1 and 2 diffusion coeffi-
cients predicted to be of order Oð1013Þ and Oð1014Þm2 s1,
respectively. The parameter a is calculated to be 0.22 and is found
to reduce as the initial drug density is increased, i.e. as more drug is
loaded initially, a larger fraction of drug exists in the non-
percolated phase. The authors also attempt to predict the release
of a combination of drugs from a stent coating. They use the same
minimisation technique, this time requiring to find six fitting
parameters. The authors conclude that the validation of their
model with experimental data confirms the mechanistic behaviour
of the mass transport phenomena within the coating and their
assumption of a biphasic state of drug phase within the coating.
Interestingly, the authors also show a plot which compares their
model prediction with Cypher release data and claim that the
model can be used to predict drug release from the Cypher stent.
However, they do not specify the values of diffusion coefficients
and a they use to generate their plots. Given that these values
are unlikely to be known a priori it seems that a numerical
algorithm approach has been adopted to find the parameter values
which best fit the data. It is interesting that the models of Hossainy
et al. and McGinty et al. have both demonstrated good agreement
with Cypher release profiles, albeit McGinty et al. compared with
in vitro data, while Hossainy compared with in vivo data. Thus a
warning must be issued: a good fit to experimental data does not
necessarily confirm that the model is correct. With certain param-
eter values, it may be possible to show that a set of experimental
data is fitted well by several different models.
While not focussing specifically on DESs, Siepmann and Siep-
mann [12] in their review onmodelling of diffusion controlled drug
delivery provide a series of analytical solutions for drug release from
reservoir andmonolithic drug delivery systems, some of whichmay
be applied to DESs under certain assumptions. Many of their solu-
tions are early or late time approximations, and in some cases steady
state solutions. The reader is referred to [12] for full details.
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Whilst the release of drug from the aforementioned types of
stents seems to be well described by diffusion alone, this is not
the case for all DESs. Realising that the release mechanism may
not be as simple as pure diffusion, Tzafriri et al. [2] chose to write
down a two-part equation to describe drug release from the
Cypher and NEVO stents and, using a best fitting process, found
the values of the parameters of the model. Their approach was of
interest to industry since it aimed to compare and contrast the
release kinetics of two different types of stent platforms, by way
of experimentation coupled with modelling. With similarity to
Hossainy et al., their equation assumes that these stents contain
two pools of dispersed drug, one that is surface-connected and
elutes through a percolating network of drug filled pores, and
another that is embedded within the matrix and diffuses more
slowly through the percolating polymer phase. Thus they utilised
the following equation for the mass of drug released from the
Cypher and NEVO stents:
Mstentð0Þ MstentðtÞ ¼ Mf0 1 eKf0 t
 
þ Q sus
ﬃﬃ
t
p
; ð5Þ
where Mstentð0Þ; Mf0 ; K f0 and Q sus denote, respectively, the initial
load of drug, the initial pool of first order eluting drug, rate constant
and Higuchi rate constant. This equation, however, is empirically-
based and does not satisfy mass conservation principles: the mass
of drug released eventually tends to infinity as time increases. As
a result, while their data is well-fitted to this equation for this set
of experiments, it is unlikely that their model may be used in a pre-
dictive capacity. It is noteworthy that Tzafriri et al. found that the
Nevo release data fit (5) best when Mf0 ¼ 0, suggesting that for this
stent there is only one mode of elution.
Building on the idea that drug coated on stents may exist in two
distinct forms (dissolved and undissolved), McGinty et al. [9]
provided a series of diffusion–dissolution based models which all
admitted analytical solutions. Their intention is that these
analytical solutions, when used in conjunction with appropriate
experimental data, may be easily utilised by researchers or indus-
trialists to help clarify the release mechanism (s) and thus aid in
the development of DESs. The first model they present couples dif-
fusion with instantaneous dissolution and is based on the early
works of Higuchi [13]. The model assumes that drug is initially
present at a concentration (C0) exceeding solubility (Cs) in the
coating and that the drug is dissolved instantly on a moving front
which penetrates into the coating. They provide the solution
(under sink conditions) in two parts. The first part describes the
mass of drug released up until the time (tH) where the drug
concentration throughout the coating falls below solubility. The
second part describes the duration of the release:
MfracðtÞ ¼
ﬃﬃ
t
p
LpC
0
h C0  Cs
 
þ
2
ﬃﬃﬃﬃﬃﬃ
Dp
p
Cs 1 exp  h24Dp
n o 
ﬃﬃﬃ
p
p
erf h
2
ﬃﬃﬃﬃ
Dp
p
	 

8>><
>:
9>>=
>;; t < t
H:
ð6Þ
MfracðtÞ ¼ 1
8Cs
C0p2erf h
2
ﬃﬃﬃ
Dp
p
	 


X1
n¼1
exp
Dpð2n1Þ2p2
4Lp
t
n o
R erf
ð2n1ÞipDptHþL2p
2Lp
ﬃﬃﬃﬃﬃﬃﬃ
DptH
p
	 
 
2n1ð Þ2
8>>>><
>>>:
9>>>>=
>>>;
t > tH
ð7Þ
where tH ¼ ðLp=hÞ2 and h is found by solving
2
ﬃﬃﬃﬃﬃﬃ
Dp
p
r
Cs
C0  Cs
¼ herf h
2
ﬃﬃﬃﬃﬃﬃ
Dp
p
 !
exp
h2
4Dp
( )
: ð8Þ
The error function, erf, is a standard mathematical function and is
discussed in, for example, Crank [14]. McGinty et al. also provide
an analytical solution for the case of release governed by diffusion
and dissolution involving a linear first order reaction. The drug is
assumed to exist in two forms: dissolved (or free) (Cf ) and undis-
solved (or bound) (Cb). The drug can dissolve into the free form
via the forward reaction rate K1 and then transform back into bound
drug via the backward reaction rate K2:
@Cf
@t
ðx;tÞ¼DP @
2Cf
@x2
ðx;tÞþK1Cbðx;tÞK2Cf ðx;tÞ; 0< x< Lp; t>0;
ð9Þ
@Cb
@t
ðx;tÞ¼K1Cbðx;tÞþK2Cf ðx;tÞ 0< x< Lp; t>0: ð10Þ
In deriving their solution they assume that all of the drug is initially
in undissolved form and they impose a zero-flux condition at the
impermeable stent and a sink condition at the boundary with the
release medium. The solution is
MfracðtÞ¼1exp K1tf gþ2K2K1Dp
L2p

X2
j¼1
X1
n¼1
sjnþK1
 2 exp sjn tf gexp K1tf g
K1þsjn
þexp ðK2þK1Þtf gexp K1tf g
K2
	 

sjn s
2
jn
þ2K1sjnþK1ðK2þK1Þ
 
K2þK1þsjn
 
þ2K1Dp
L2p
X2
j¼1
X1
n¼1
sjnþK1
 2
exp sjn t
 exp ðK2þK1Þtf g 
sjn s
2
jn
þ2K1sjnþK1ðK2þK1Þ
 
K2þK1þsjn
 
where
2s1n ¼  K2 þ K1 þ
Dp
4L2p
p2 2n 1ð Þ2
 !
þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
K2 þ K1 þ Dp
4L2p
p2 2n 1ð Þ2
 !2
 K1Dp
L2p
p2 2n 1ð Þ2
vuut
2s2n ¼  K2 þ K1 þ
Dp
4L2p
p2 2n 1ð Þ2
 !

ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
K2 þ K1 þ Dp
4L2p
p2 2n 1ð Þ2
 !2
 K1Dp
L2p
p2 2n 1ð Þ2
vuut :
ð11Þ
They show that by taking the limit as K2 ! 0, the equivalent expres-
sion for a non-reversible reaction can be derived:
MfracðtÞ ¼ 1 exp K1tf g
 8K1
p2
X1
n¼1
exp
Dp
4L2p
ð2n 1Þ2p2t
 
 exp K1tf g
ð2n 1Þ2 K1  Dp4L2p ð2n 1Þ
2p2
	 
 : ð12Þ
They argue that, when compared with appropriate experimental
data, the solutions can readily confirm the release mechanism(s)
and further, allow estimation of the various parameters of the sys-
tem via the inverse problem. Pontrelli et al. [15] have adopted a
similar approach to modelling drug release from the coating. They
too assume that drug within the coating exists in two phases. They
neglect diffusion within the solid phase so that their equations are
essentially (9) and (10) albeit with their parameters defined differ-
ently to include the effects of partitioning of drug between the two
phases and the porosity of the coating.
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2.2. Drug release from stents with biodegradable and erodible coatings
Up until now we have focussed on models which describe the
drug release from first and second generation DESs. Newer genera-
tion DESs which have focussed on biodegradable polymers and
polymer-freemodified surface designs are likely to havemore com-
plicatedmechanisms of release, and so it is of industrial relevance to
consider these types of stents in their own right. In the case of stents
with biodegradable polymeric coatings, the drug release may
involve diffusion, erosion and possibly dissolution and/or swelling
[16,17]. However, in the case of polymer-free stents, it is less clear
how the sustained release is obtained and how this may be mod-
elled. Because of the complexities involved in systems which
degrade as they release drug, amodelwhich is shown to be accurate
for one systemmay be useless for another. Nevertheless, we discuss
here some of the published models in the literature, but invite the
reader to refer to the specific articles for full details. Before doing
so, it is useful to clarify what is meant by some of the common pro-
cesses which appear in these models: hydration, degradation and
erosion. Hydration is simply the process of combining with water.
Degradation is a chain scission process which involves the breaking
of polymeric chains by free radicals. On the other hand, erosion is
material loss froma systemand can be either surface erosion or bulk
erosion. With surface erosion, water intrusion into the polymer is
slow compared with the rate of degradation, thus the polymer is
‘eaten away’ from the outside to the inside. With bulk erosion, the
rate of degradation is slow compared with the rate of water uptake
and so the entire system is rapidly hydrated and degradation occurs
throughout the whole material equally.
Prabhu and Hossainy [18] focused specifically on the degrada-
tion and release of everolimus from a polylactic (PLA) stent coating
and validated their compartmentalised model using in vitro data.
The model considers two non-linear reactions: the hydrolysis (by
water intrusion) of PLA to produce oligomers and lactic acid and
the hydrolysis of oligomers to produce lactic acid. Five reaction dif-
fusion equations are presented to describe the temporal and spatial
evolution of the concentrations of water, PLA, oligomers, lactic acid
and everolimus. The model equations were solved using an
iterative finite difference approach which updates estimates of
the various parameters via comparison with the experimental
data. They indicate that autocatalysis (i.e. a reaction where the
reaction product itself is the catalyst of the reaction) is important
and cannot be ignored. While not directly focussing on DESs, Siep-
mann and Gopferich [19] provided a review of the mathematical
modelling of bioerodible polymeric drug delivery devices. They
consider only systems where the drugs are physically immobilized
within a water insoluble polymeric matrix. They stress that accu-
rate physiochemical characterisation of the investigated system
is an absolute pre-requisite for the appropriate mathematical mod-
elling of the device, and as such they detail techniques to experi-
mentally characterise degradation and erosion. These can help
identify whether the erosion is surface or bulk and assist in clarify-
ing the time-dependence of the diffusion coefficients. Among the
models presented are those of Heller and Baker [20] which
involves modification of the Higuchi equation to include a time-
dependent permeability as a result of bulk erosion, the model of
Lee [21] which lends itself to an approximate analytical solution
for drug release from thin eroding films and the models of Joshi
and Himmelstein [22,23] which accounts for acid producing spe-
cies that accelerate matrix hydrolysis. The authors comment that
modelling efforts should try to take into account the in vivo
conditions since, for example, cellular tissue reactions can affect
the degradation process. Again, not referring specifically to DESs,
Rothstein et al. [24] present a unified model for the prediction of
controlled release from surface and bulk eroding polymer matrices
which also accounts for the transition from surface eroding to bulk
eroding behaviour during the course of degradation. Soares and
Zunino [25] introduced a mixture model for water uptake, degrada-
tion, erosion and drug release from polydisperse polymeric net-
works. Each constituent of the model represents chains of an
average size. A multiscale description of degradation and erosion
is proposed, combining the molecular description of scission with
Fick’s macroscopic laws of diffusion. The approach adopted here
describes degradation by means of the time evolution of weight
fractions of polymeric constituents of average degree of polymeri-
sation. They argue that the key advantage of their model is the fact
that polymer degradation is described as an individual chemical
reaction. Rossi et al. [26] modelled a bioresorbable DES based on
detailed constitutive equations and taking into account the main
physical and chemical mechanisms involved in coating degrada-
tion, drug release and restenosis inhibition. Their results were ver-
ified against selected in vitro and in vivo data available in the
literature. Formaggia et al. [27] considered a two dimensional
dissolution–diffusion model which also included surface erosion.
Similarly to McGinty et al. [9], they too realised that as a result of
the industrial manufacturing coating process, the drug may exist
in the coating in a form which needs to dissolve before it can
diffuse. They consider the drug in polymer as two separate phases:
a dissolved phase and a solid phase with concentrations Cf and Cb,
respectively. Only dissolved drug is permitted to diffuse. Thus they
include a source term in the diffusion equation to account for the
solid phase dissolution. The dissolution term is non-linear and is
based on a reformulation of the empirical Noyes–Whitney equation
[28] with the dissolution coefficient, K1, possibly space and time
dependent. The resulting equations in the polymer coating are
@Cf
@t
r  DprCf
  ¼ K1C2=3b Cs  Cf ; ð13Þ
@Cb
@t
¼ K1C2=3b Cs  Cf
 
: ð14Þ
3. Modelling drug transport through the arterial wall
Modelling the release of drug from arterial stents is only one
part of the story. What happens to the drug after it is released
in vivo is of more clinical interest and certainly more difficult to
model. Clinicians advise that a uniform drug concentration should
be attained across the arterial wall, and the concentration should
be maintained within some therapeutic window. Thus an under-
standing of the structure and components of the arterial wall is
crucial. The arterial wall is a porous heterogeneous structure, con-
sisting of three distinct layers (see Fig. 2). Closest to the lumen is
the intima, followed by the media and finally the adventitia [29].
The intima consists of the sub-endothelial space and the endothe-
lial layer of cells, known as the endothelium. This layer is crucial to
the control of the normal function of the artery, through its medi-
ation of relaxation and contraction and via its control of smooth
muscle cell proliferation within the underlying media layer. The
internal elastic lamina forms the outermost part of the intima.
The media region comprises smooth muscle cells, collagen and
elastin. Finally, the outermost layer of the arterial wall is the
adventitia. The adventitia tethers the artery to perivascular tissue,
and contains cells known as fibroblasts as well as a network of
small blood vessels, called vasa vasorum, which act as a blood sup-
ply to the adventitia and provide a clearance mechanism for drugs
released into the artery wall.
3.1. The advection–diffusion–reaction equation
The processes that govern mass transport through the arterial
wall are diffusion, convection and binding (reaction). If the arterial
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wall was a single layer, then the drug transport could be described
by an advection–diffusion–reaction equation of the form:
@C
@t
þ v rC ¼ Dr2C  R; ð15Þ
where, here, C is the concentration of drug in the wall, v is the trans-
mural convection (as a result of the pressure difference across the
wall), D is the diffusivity tensor and R represents the binding ‘reac-
tion’, whichmay take several forms. For a derivation of the transport
equation the reader is referred to, for example, de Monte et al. [30].
Actually, we require an equation of the form (15) for each layer of
the arterial wall since the material properties are different in each
layer. In particular, the different composition of each layer results
in differing porosities, diffusion coefficients and binding properties.
There is evidence that within each layer, anisotropy may be impor-
tant. For example, diffusionwithin the tissue has been reported to be
anisotropic [31,32] with the diffusion coefficient in the radial direc-
tion possibly as much as 100 or 1000 times less than in the circum-
ferential and axial directions. The diffusion coefficients in the
following models incorporate the effects of porosity and tortuosity
and are sometimes referred to as ‘effective’ diffusion coefficients.
The first mathematical treatment of arterial drug transport
seems to have been by Zunino who built on the earlier experimen-
tal works of Creel et al. [33], Hwang et al. [34], Lovich et al. [35],
Hwang and Edelman [36] and Lovich and Edelman [37]. The pur-
pose of Zunino’s work was to show how mathematical models
and numerical simulations can help to identify the physical prop-
erties of the stent coating in order to ensure a desired drug release
rate. In his model, Zunino assumed the transport was via convec-
tion and diffusion with instantaneous reaction. Volume averaged
drug concentrations, C, defined as the amount of drug in the fluid
phase plus the amount of drug bound with the tissue, divided by
the considered control volume, were utilised. Zunino related the
fluid phase drug concentration, Cf , to the concentration of drug
in a control volume, via Cf ¼ C=ðK/Þwhere / represents the poros-
ity of the medium and K is the partition coefficient which defines
the equilibrium ratio of bound drug within the tissue with respect
to drug dissolved in the fluid. He proposed the following equation
in two dimensions:
@C
@t
þr  DrC þ cu
K/
C
	 

¼ 0; ð16Þ
where 0 < c < 1 accounts for possible frictional effects between
drug molecules and the pores. Here u is defined as the filtration
velocity. Zunino’s most important finding was that drug retention
strictly depends on the properties of the drug inside the wall and
is not influenced by the characteristics of the carrier.
3.2. Modelling drug binding in arterial tissue
While the convective and diffusive element of the drug
transport is well established, the issue of drug binding is more
controversial. Some authors have assumed equilibrium models
[6,38,39], while others have considered simple loss terms
[7,8,40,41]. More recently, non-linear saturable binding models
have been utilised [2,42–44].
3.2.1. Models involving linear reaction terms
The simplest form of reaction is a loss term which accounts for
consumption of drug in the system (for example, to cells or
through vasa vasorum blood vessels). If drug is lost from the system
in proportion to some parameter, say b, then the reaction termmay
be written as:
R ¼ bC: ð17Þ
Pontrelli and de Monte [40] proposed a model which incorporated
(15) along with binding of the type (17). Their most sophisticated
model [41] has the benefit of being multi-layered, although only
one-dimension is considered. In each layer, the drug transport is
described by
/
@Ci
@t
ðx; tÞ þ 2ci
@Ci
@x
ðx; tÞ ¼ Di @
2Ci
@x2
ðx; tÞ  biCiðx; tÞ; ð18Þ
where the subscript i indicates the ith layer, 2ci represents a con-
stant characteristic convection parameter and Di represents the
effective diffusion coefficient. Pontrelli and de Monte’s model has
the advantage of admitting an analytical solution.
McGinty et al. [6] utilised a more sophisticated reaction model
based on the idea that the drug in the tissue exists in two phases:
an extracellular fluid phase and a solid cellular phase. If in equilib-
rium the concentration of drug in the bound solid phase (Cb) is
some constant, say K, times the concentration in the extracellular
fluid phase (C), then we may have the following reaction term:
Fig. 2. The structure of the arterial wall.
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R ¼ 1 /ð Þ @Cb
@t
¼ aðC  Cb=KÞ; ð19Þ
where a is a rate constant. Absorbing the porosity terms into a for-
ward reaction uptake rate kf and backwards reaction rate kr , the
McGinty model becomes
@Cb
@t
¼ kfC  krCb; ð20Þ
which is identical to the form of reaction considered by Horner et al.
[38] and Abraham et al. [39]. Horner et al. conclude in their analysis
that a single species drug delivery model cannot accurately predict
the distribution of bound drug and so a two-species approach that
includes reversible binding is essential.
3.2.2. Models involving non-linear reaction terms
While it is generally appreciated that a reversible reaction is
required to describe binding, the form need not be linear. In partic-
ular, if we consider the drug binding process as a ligand binding to
a receptor to form a complex then we can utilise some ideas from
molecular cell biology. Consider the following equilibrium binding
for a reversible reaction between a receptor (r) and ligand (l) to
form a receptor/ligand complex (c) [45]:
lþ r 
kf
kr
c;
where, here, kf and kr are termed the association and dissociation
rate constants, respectively. Assuming that each ligand binds only
with one binding site (or receptor), Lauffenburger and Linderman
present the following first order reversible saturable equation
describing the time rate of change of concentration of the complex:
dc
dt
¼ kf rl krc; ð21Þ
where here kf characterises the velocity of the second-order inter-
action between the receptor and ligand while kr characterises the
velocity of the first-order breakdown of the receptor/ligand com-
plex. It will be convenient to refer to receptors as unoccupied bind-
ing sites and receptor/ligand complexes as occupied binding sites. It
will also be useful to define a binding site conservation condition:
bðtÞ þ aðtÞ ¼ bmax; ð22Þ
which states that at any time the number of occupied binding sites,
b, plus the number of unoccupied binding sites, a, is equal to the
local density of binding sites, bmax.
Sakharov et al. [42] seems to be the first group to have applied
this type of binding model within a DES setting. They provide the
following binding equation which describes the rate of change of
concentration of unoccupied binding sites:
dCa
dt
¼ kfCCa þ kr bmax  Caf g; ð23Þ
where, here, C and Ca denote the concentrations of free drug and
unoccupied binding sites, respectively. Tzafriri et al. [43] provide
an alternative equation in terms of the rate of change of occupied
binding sites.
dCb
dt
¼ kfC bmax  Cbf g  krCb; ð24Þ
where Cb is the concentration of occupied binding sites (bound
drug). It is straightforward to show that (24) is equivalent to (23)
by substituting (22) into (23). This type of binding model has also
been adopted by other authors [44]. It is well established that in
addition to binding to specific receptors, there is also the occurrence
of relatively weak non-specific binding caused by association of
drug with membrane constituents or by trapping of drug in the
extracellular medium [45]. While it is believed that only the
receptor (specific) binding is linked to the desired biological effect,
binding to non-specific sites will nevertheless, have an impact on
drug distribution. Taking this into account, Tzafriri et al. [2] in their
most recent work include two equations for drug binding in arterial
tissue: one for specific binding to receptors (24) and another for
non-specific binding to general extracellular matrix (ECM) sites:
dCbns
dt
¼ kfnsC bmaxns  Cbnsf g  krnsCbns ; ð25Þ
where here the subscript ns indicates non-specific. While determin-
ing which type of binding model is most appropriate is not within
the remit of this review, it is worth stating that Tzafriri et al. [43]
found that while a non-saturable linear model of the type (20)
agrees with a saturable model of the type (24) in simulating the
predicted arterial distribution of heparin, this is not the case for
more lipophillic drugs like paclitaxel and sirolimus. They argue that
the nonsaturable binding model significantly underestimates the
depth of paclitaxel and sirolimus penetration while overestimating
the total arterial deposition. However, no experimental results are
presented to compare with the simulations. On the other hand,
Zhu et al. [46] considered a compartmental model of the type (20)
to describe uptake of drug into SMCs and demonstrated good
agreement with experiments. It is certainly true that the drug will
bind to binding sites in the tissue and on/in cells [2,47,48] although
the strength of the affinity will likely vary substantially with the
particular drug under consideration. Furthermore, it is not clear
how the density of the binding sites may be easily measured
in vivo. Thus it may be that this binding model is specific to a par-
ticular class of drugs and not suitable for more general compounds.
A greater understanding of the binding process would undoubtedly
assist with model development.
4. Modelling the coupled stent-wall system
So far we have reviewed the modelling of drug release from
DESs and drug transport through arterial tissue, both of which
are important problems in their own right. In reality, of course,
the stent and arterial wall are a coupled system. Thus, to accurately
model the in vivo situation we are obliged to consider the interac-
tion between the stent and the tissue. The coupled problem has
received much attention in the literature, with most of the models
necessarily requiring to be solved numerically due to the complex-
ity of the problem. One exception is the model due to Pontrelli and
de Monte [40] who consider diffusion based drug release from a
non-erodible polymer-coated stent (Eq. (1)) coupled with a con-
vection–diffusion equation in the arterial wall which also accounts
for drug consumption via a linear reaction (Eq. (18)). They assume
that where the polymer rests against the bare metal of the stent
there is zero flux and that the initial concentration within the
polymer is some constant C0. At the polymer/tissue interface the
total flux is assumed to be continuous, and a top-coat on the
polymer is allowed for:
Dp
@Cp
@x
¼ D @C
@x
 2cC; ð26Þ
Dp @Cp
@x
¼ P Cp
Kp/p
 C
K/
 !
; ð27Þ
where, here, P denotes a parameter with units m s1 and the sub-
script p denotes parameters associated with the polymer. At the
perivascular end of the tissue they assume that C ¼ 0. The signifi-
cance of Pontrelli and de Monte’s work is that they were able to
obtain an analytical solution for the drug concentration in the
polymer and the media tissue region (through separation of
variables), allowing drug concentrations to be readily computed.
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They were able to show that the presence of a relatively small
advection lowers the observed wall concentration curves due to
the convective velocity sweeping away drug from the wall and that
at intermediate and later times, a more uniform concentration is
guaranteed. In addition they found that increasing the drug
consumption rate diminishes the concentrations but preserves the
profile shapes. The drug diffusivity in the wall was shown to greatly
influence the residence time of the drug. The relevance of this find-
ing is that drugs which exhibit a smaller diffusivity in the arterial
wall will be retained longer. Their work has been extended to
multi-layers [41].
While the models of Pontrelli and de Monte are an important
contribution to the field, they are unable to model the spatial
and temporal concentration of bound drug. Indeed, the drugs used
in DESs are usually targeted to bind to specific receptors on/in
SMCs. One of the first stent/tissue models which encompassed
convection, diffusion and uptake into SMCs within the porous
media was presented by McGinty et al. [6]:
@Cp
@t
ðx; tÞ ¼ Dp @
2Cp
@x2
ðx; tÞ; x 2 ð0; LpÞ; t > 0; ð28Þ
/
@C
@t
þ v @C
@x
¼ D @
2C
@x2
 a C  Cb
K
	 

; x 2 ðLp; Lp þ LÞ; t > 0; ð29Þ
ð1 /Þ @Cb
@t
¼ a C  Cb
K
	 

; x 2 ðLp; Lp þ LÞ; t > 0; ð30Þ
where C and Cb denote the volume averaged concentration of drug
in the extracellular and cellular regions, respectively [6]. The
parameters /; v; D; a; K and L denote the porosity, magnitude of
effective transmural convection, effective drug diffusion coefficient
in the media, drug uptake rate constant, partition coefficient and
thickness of the media region. Eq. (30) expresses the rate of uptake
of drug by the cells: it is initially proportional to the free drug C but
that proportionality diminishes with increasing Cb until the carry-
ing capacity (or partition coefficient) of the drug is reached at which
point the uptake becomes zero. This system of equations allows for
an exchange of drug between the extracellular phase and the cells
which is dependent on the concentration in the extracellular phase.
The boundary conditions they adopted at the interface between the
polymer coating and the arterial tissue were continuity of the
relative fluxes (Eq. (26) with v replacing 2c) and continuity of fluid
drug concentration. They assumed that the flux of drug out of the
media was proportional (via some parameter d) to the concentra-
tion at the interface between the media and adventitia to provide
the final boundary condition:
D @C
@x
þ vC ¼ dC: ð31Þ
Their model was also extended to include the adventitia region
(where fibroblast cells were modelled in a similar way to SMCs), a
topcoat of polymer to slow the release of the drug, and one of the
first models of atherosclerotic plaque (modelled using an
equilibrium model in the same way as SMCs uptake).
McGinty et al. simulated the problem using a finite difference
scheme and conducted a thorough sensitivity analysis which
allowed them to infer the importance of the parameters in their
model. They found that the results were particularly sensitive to
fluctuations in the magnitude of the transmural velocity, and to
changes in the drug uptake rate and partition coefficient. Small
changes in these parameters were found to result in a large large
variation in clinically significant indicators such as uniformity of
the concentration profile, maximum cellular drug concentrations
and therapeutic period (the time period over which the cells are
exposed to drug levels within a clinically relevant therapeutic
window). The significance of this finding is that it is important
that reliable measurements/estimates of these parameters are
obtained. In line with the findings of Pontrelli and de Monte, they
found that as the magnitude of the transmural velocity was
increased, the wall concentration profile became more uniform
but they also noted that the therapeutic period was significantly
reduced while the maximum cellular concentration attained was
increased. Increasing the drug uptake rate can reduce the thera-
peutic period, while increasing the partition coefficient can signif-
icantly increase the therapeutic period. Their simple model of
plaque suggested that the plaque could act as a reservoir for the
drug, ensuring that patients with a higher degree of atherosclerosis
may receive therapeutic levels of drug for longer than those with a
lesser degree of plaque. This finding is in contrast to an experimen-
tal study in the literature [49] where it was concluded that drug
concentration was inversely correlated to lipid concentrations.
The McGinty et al. model did, however, neglect the intimal region
of the arterial wall and the endothelium layer of cells (as indeed
have several other authors). Their justification for this is that the
endothelium is severely damaged when a stent is inserted and in
some cases is completely removed; and indeed the properties of
the intima may not be too different from those in the media. In a
subsequent paper, McGinty et al. [50] combined their earlier work
[6] with that of Pontrelli and de Monte [40] to obtain an analytical
solution for the drug concentration both in the target cells (Cb) and
the interstitial region of the tissue (C) in terms of the drug release
concentration at the interface between the polymer and the tissue.
They showed that when the polymer region and the tissue region
are considered as a coupled system, under certain assumptions,
the drug release concentration satisfies a Volterra integral equation
which must be solved numerically in general. The drug concentra-
tions, both in the cellular and extracellular regions, are then
determined from the solution of this integral equation and then
used in deriving the mass of bound drug in the cells.
Building upon their earlier works, Pontrelli et al. [15] presented
a semi-analytical expression for the drug concentration and mass
in each layer of the arterial wall for the case where the drug must
dissolve in the polymer before it can diffuse. The equations for drug
transport through the tissue layers were identical to their earlier
models [40] but now the equations for the drug in the coating were
similar to (9) and (10):
@Cf
@t
ðx; tÞ ¼ DP @
2Cf
@x2
ðx; tÞ þ Kp/p
tf
Cb  Cf
Kp/p
 !
; ð32Þ
@Cb
@t
ðx; tÞ ¼ qf
tf
Cb  C
Kp/p
 !
: ð33Þ
Here tf is a function of the physio-chemical properties of the sub-
stance and of the microstructure of the porous material and qf is
the ratio of non-solid volume to solid volume. In their analysis, Pon-
trelli et al. exploit a perturbation solution method (noting that the
coating thickness is much less than the penetration distance) as
an alternative to numerical integration. They conclude that the
solid–liquid mass transfer time can have a significant influence on
the time taken for drug to be released from the coating as well as
the on the drug mass distribution in the wall.
The coupled models discussed so far, all being one-dimensional,
have allowed for analytical or semi-analytical solutions due to the
particular simplifications that were made. However, in general,
analytical solutions are extremely difficult to obtain, especially
when two or three dimensions are considered. Zunino [8], in his
early model, considered a two-dimensional geometry and solved
the diffusion equation in two dimensions coupled with an
advection diffusion Eq. (16) for the drug concentration in the arte-
rial wall. Zunino obtained the velocity field by consideration of
Darcy’s Law and applied a finite element approach to solving the
resulting equations. Zunino was able to show that a significant
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amount of drug may be lost from the lumen (up to 70% for heparin
and 60% for paclitaxel) and this is related to the binding and diffu-
sion properties of drug in the tissue. This has implications for stent
manufacturers when considering the type of drug to include on
their stent. Due to the zero-flux conditions imposed by McGinty
et al. [6] and Pontrelli and de Monte [7,40] in their one-dimen-
sional setting, this is a feature that they neglect and may well lead
to over-prediction of drug concentrations in the arterial wall. Two-
dimensional models in simplified geometries were also computed
by [32,51], among others.
A number of three-dimensional models have also been devised.
Moving to three dimensions opens up the possibility of considering
more realistic geometries than the simplified cases considered in
the lower dimensional models. However, these models require to
be solved numerically and often make a number of assumptions
to facilitate quick computation or to reduce the complexity of
the numerical code. Weiler et al. [52] provided a broad generaliza-
tion of the works of [53–55]; a three-dimensional model of drug
transport in the lumen and the arterial wall. Laminar steady flow
was assumed in the lumen and the steady diffusion equation (no
convection or reaction) in the arterial wall. Through numerical
simulation using commercial finite element software, they found
that the highest rates of mass transfer occurred at the forward por-
tion of the stent and the rate of drug delivery to the lumen was
greater than that to the tissue. The implication is that not all of
the drug on the stent will actually reach the tissue. Indeed many
commercially available stents now only coat drug abluminally.
While not the focus of this review, a number of studies have con-
sidered the interaction of blood flow and drug release. Zunino
et al. [56] found that a significant fraction of the drug that is
released into the blood flow resides into the recirculation down-
stream of the struts, where it can be absorbed into the arterial wall.
They also found that the interaction between the blood flow and
the struts can result in very complex flow patterns [57]. Borghi
et al. [58] also considered the interaction with flow in their model,
which also included a nonlinear model of binding in the tissue as
well as a degradable polymer matrix. The reader is referred to
these articles for further details.
Horner et al. [38] appear to be one of the first authors to provide
a three-dimensional reaction–diffusion–convection model in a
realistic geometry. They stress the importance of considering two
phases of the drug (bound and unbound) and use a first order reac-
tion kinetics model to describe the transfer of drug between the
two phases. They utilise ABAQUS (commercial finite element anal-
ysis software) to obtain a realistic geometry of a deformed stent
and vessel wall and then employ FLUENT (commercial software
with flow modelling capabilities) to solve their transport equa-
tions. Their three-dimensional setting allows for the consideration
of anisotropic diffusion in the arterial wall. They do, however,
make three significant simplifications. Firstly, they model the arte-
rial wall as a linear homogeneous solid and do not distinguish
between the intima, media and adventitia. Secondly, despite calcu-
lating the transmural velocity field, they assume this is fixed when
solving the transport equations. Perhaps the most unrealistic
assumption is that the drug concentration on the stent remains
constant and does not deplete. They find that deposition patterns
tend to follow the pattern of the stent struts and that the drug is
able to penetrate deep into the arterial wall. The pattern of bound
drug becomes less uniform as the Peclet number is increased,
eventually becoming restricted to areas adjacent to the struts, as
convection dominates over diffusion. Feenstra and Taylor [59], in
their earlier work, utilize a sequential porohyperelastic transport
approach and do not apply any of these assumptions. In particular,
they calculate the interstitial fluid velocity field using a stent
deployment simulation, rather than assuming it is known a priori.
A common difficulty with turning to higher dimensional models is
the increased computational cost associated with accounting for
multiple space scales. To overcome this, Vergara and Zunino [60]
proposed a model reduction strategy to derive approximate
boundary conditions that significantly reduce the computational
burden.
Only two groups thus far have attempted to model the coupled
problem of drug release from DESs and arterial deposition which
involves a nonlinear saturable binding model. Tzafriri et al. use
the formula (5) to describe the release of drug from two types of
non-erodible stents (Cypher and Nevo) and from this the rate of
change of mass is easily derived:
dMstent
dt
¼ K f0Mf0 exp K f0 t
  Q sus
2
ﬃﬃ
t
p : ð34Þ
Within the media layer of the tissue they utilise the one-
dimensional convection–diffusion–reaction equation (in a
cylindrical co-ordinate system)
@C
@t
þ @Cb
@t
þ @Cbns
@t
¼ D @
2C
@r2
þ D
r
@C
@r
 v @C
@r
ð35Þ
and couple the release to the tissue equation through the following
flux boundary condition:
 D @C
@r
þ vC ¼  fwall
SlumenAdrug
dMstent
dt
ð36Þ
¼ Fluxin; ð37Þ
where fwall; Slumen and Adrug are the efficiency factor for delivery into
the arterial wall, the surface area of the blood wall interface and the
drug’s molecular weight, respectively. The time rate of change of
the concentrations of specifically bound drug (@Cb=@t) and of the
non-specifically bound drug (@Cbns=@t) are given by (24, 25). They
assumed C ¼ 0 at the perivascular end and simulated the solution
numerically. In addition to this, by assuming that once drug concen-
trations have traversed the thickness of the arterial wall, concentra-
tion gradients in the wall quasi-statically track the declining rate of
drug elution, they solved the steady-state version of the model and
also neglected the curvature term. They find that once quasi-steady
state is established, the content of free drug in coronary tissue
should proportionally track the rate of drug elution:
CfreeðtÞ ¼ AdrugFluxinðtÞqtissuev
1 1 exp Pef g
Pe
	 

; ð38Þ
where qtissue and Pe are the density of wet arterial tissue and the
Peclet number, respectively. By probing their analytical solution
they conclude, in conjunction with the numerical results, that the
persistence time of receptor saturation and effect is more sensitive
to duration of elution than to eluted amount. Consequently, dose
escalation is inefficient at compensating for sub-optimal duration
of elution, so that stent manufacturer’s efforts should be concen-
trated on sustaining elution rather than elevating the load. Interest-
ingly, by comparison with experiments, they find that fwall is
approximately 0.06 and 0.16 for Cypher and Nevo stents, respec-
tively, suggesting that a significant portion of drug is lost.
Most recently, Bozsak et al. [44] attempted to answer three key
questions of industrial and clinical interest: Why do some drugs
coated on stents perform differently from others when their prop-
erties appear to be similar? How important is the inclusion of a
multi-layered structure of the arterial wall? Which type of reaction
(saturable nonlinear two species model or non-saturable one
species model) captures the binding effect in the tissue? The
authors consider a two-dimensional model where drug transport
in the drug coating is governed by diffusion only and drug
transport through the arterial wall is governed by the convec-
tion–diffusion reaction Eq. (15) where the reaction takes the form
(24), i.e. a non-linear saturable binding model. In addition, Bozsak
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et al. model the drug transport in the lumen with a convection–
diffusion equation where the blood flow is assumed steady.
Kedem–Katchalsky membrane conditions are utilised to describe the
concentration discontinuity across the thin endothelium and internal
elastic lamina and continuity of flux conditions are also employed
(essentially the two-dimensional equivalent of (26) and (27)).
Three different conditions are considered at the far adventitia,
these being infinite sink, zero flux and Robin-type conditions. It
was found that the choice of boundary condition had no significant
effect on the results. The governing equations were discretized by
means of the finite element method (FEM) using the commercial
software package COMSOL Multiphysics 4.3. They conclude that
the one layer model (which includes only the medial layer and
neglects the sub-endothelial space) is incapable of predicting the
observed backflow that enters the sub-endothelial space in the
two layer model. Furthermore, the peak tissue concentration is
underestimated by 30% and as the thickness of the sub-endothelial
space increases (representing diseased arteries) the difference
between the one and two layer models become more pronounced.
Comparing the two different binding models, the authors note they
are comparable at very early times but the peak concentration pre-
dicted by the equilibrium model occurs considerably later and is
significantly higher. Matching the prediction of drug accumulation
by the equilibrium model to that of the saturable model requires a
reduction in partition coefficient while matching drug residence
time requires an increase. Clearly, both cannot be achieved simul-
taneously. Finally the authors conclude that the difference in bind-
ing properties between paclitaxel and sirolimus are due to the
greater convection-dominated transport of paclitaxel compared
with sirolimus. For paclitaxel, the drug is initially predominantly
in the free state and invades the media driven by plasma flow in
the arterial wall since the timescale for convection is faster than
that for binding. With rising levels of free drug in the wall, the
binding rate increases. Once all binding sites are saturated any
excess drug is washed out and when the stent polymer is empty
and the wall is devoid of excess drug, the transport becomes dom-
inated by unbinding. However, for sirolimus, the initial dominating
process is binding and so the binding sites become very rapidly
occupied. Once they become exhausted, a more convection-driven
phase takes over.
5. Discussion
In this article we have attempted to provide a comprehensive
review of the modelling approaches adopted to study the release
of drug from arterial stents and the redistribution in arterial tissue.
Despite the high level of complexity involved, over the past decade
real progress has been made in attempting to understand the
mechanism(s) governing the release of drug from DESs and also
in understanding the transport and binding properties of drugs in
arterial tissue. Stimulated by early experimental works [33–37]
researchers from across the globe have become increasingly inter-
ested in attempting to model these processes. A combination of
approaches have been adopted. Some authors have focussed on
trying to accurately characterise the release of drug from DES in
controlled in vitro experiments while others have applied simple
models to the in vivo situation. A number of groups have focussed
specifically on drug transport through arterial tissue and in trying
to understand the complex binding process that takes place as well
as the relative importance of convection, diffusion and reaction.
While simplified one-dimensional models can provide useful
insights into this problem, ultimately three-dimensional models
which capture the full complex geometry of the stent and the arte-
rial wall may be required. The existing three-dimensional models
in the literature all make certain simplifying assumptions, whether
it be in idealising the stent geometry, or in neglecting convection,
diffusion or binding, or in considering only single or bi-layer arte-
rial walls. Thus there is an opportunity to increase the sophistica-
tion of the three-dimensional models, whether it be incrementally
or all at once. However, caution must be exercised to ensure that
the results of the simulations are not subject to high uncertainty,
in which case the fidelity of the results may be called into question.
Thus there is still a role for simplified models, especially those
which can admit analytical solutions, in helping to ascertain the
numerous parameters of the increasingly complex models. Many
of the parameters of the most involved models are extremely diffi-
cult (or impossible) to measure experimentally in the living system
and thus new methods for approximating these parameters should
be developed by modellers and experimentalists working in
tandem. Some progress has been made on this issue with experi-
mental data complemented with values from fiber matrix and pore
theory [57,44].
Presently, the stent manufacturers are predominantly con-
cerned with mechanical integrity of the device and as such the
stent design is usually the first consideration. The stent must be
flexible and expandable and stay in situ after deployment. During
the expansion process the stent should undergo minimum short-
ening and after implantation should conform to the natural geom-
etry of the vessel without any unnatural straightening [5].
Circumferential strength is another key component; without this
the stent will collapse under the strain of the artery. Furthermore,
the materials used must be bio-compatible and must not fracture.
But it is no good having a stent which is mechanically sound but
does not elute drug in a favourable fashion. The release of the drug
must be controlled so that it elutes over a defined period of time
and, furthermore, the drug concentration in the arterial wall
should ideally be maintained between therapeutic and toxic levels
over and beyond the period of release. Taking this into account, it
would seem that the drug release and uptake is intrinsically linked
to the stent design. Ideally the stent should be optimised, both in
terms of the mechanical design as well as drug loading so that
the required clinical outcomes are realised. This optimisation is
further complicated by the observed variation in lesion composi-
tion and other underlying health conditions of the patient. Thus
a single optimised stent design is simply unrealistic, but it may
well be possible to develop an optimised stent for a set of different
situations. Certainly, in light of increased understanding of the
drug release and arterial binding processes there is an opportunity
to design stents to achieve desired clinical outcomes.
Stent manufacturers have demonstrated consideration of
clinical outcomes in recent stent designs which have included bio-
degradable polymers, fully biodegradable structures and polymer
free designs. Whilst these tackle the problem of having a perma-
nent polymer in situ, the clinical outcomes have been observed
to be largely equivalent to their non-erodible polymer coated
counterparts [61]. To date there appears to be limited mathemati-
cal modelling of these more advanced stents which couples drug
release with arterial transport: the only example seems to be the
work of Borghi et al. [58]. Such modelling may shed light on how
these devices may be improved to realise the desired clinical
outcome.
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